View Cart  

FDA Green-Lights ViroPharma’s Cinryze, rHUPH20 Studies

A A
The FDA is allowing ViroPharma and Halozyme Theraputics to move forward with clinical studies of subcutaneous Cinryze in combination with the human hyaluronidase enzyme rHuPH20 to prevent angioedema attacks.

To View This Article:

Login

Subscribe To Drug Industry Daily